Mankind Pharma Q1FY26 Results: Revenue Surges 24.5% YoY to ₹3,570 Cr, EBITDA Margin Expands to 23.8%

New Delhi, July 31, 2025 — Mankind Pharma Ltd (NSE: MANKIND, BSE: 543904) delivered a robust performance in the first quarter of FY26, reporting a 24.5% YoY jump in consolidated revenue to ₹3,570 crore, driven by strong domestic sales, exponential export growth, and continued momentum in the consumer healthcare segment. EBITDA stood at ₹850 crore with an expanded margin of 23.8%, while the company declared an interim dividend of ₹1 per share as it celebrates its 30th anniversary.

Consolidated Financial Performance

In Q1 FY26, the company delivered a robust operational performance, with Revenue from Operations rising by 24.5% year-on-year (YoY) to ₹3,570 crore, up from ₹2,868 crore in Q1 FY25. On a sequential basis, revenue also improved by 15.9% from ₹3,079 crore in Q4 FY25, reflecting healthy demand and volume growth.

EBITDA stood at ₹850 crore, marking a YoY growth of 25.8% and a quarter-on-quarter (QoQ) increase of 24%, supported by operational efficiencies and improved realisations. EBITDA margin expanded to 23.8%, up by 20 basis points (bps) YoY and 150 bps QoQ.

However, Profit After Tax (PAT) declined 17.4% YoY to ₹445 crore, compared to ₹538 crore in the same quarter last year, largely due to a high base effect and normalisation of one-off benefits recorded earlier. On a sequential basis, PAT saw a modest rise of 3.6% over ₹429 crore in Q4 FY25.

The Diluted Earnings Per Share (EPS) came in at ₹10.6, down 20.1% YoY, but showed a marginal improvement of 3% QoQ.

Business Highlights

Domestic Formulations

• Domestic revenue rose 18.9% YoY, supported by base business growth and BSV consolidation.
• Prescription market share expanded from 4.8% in Mar-25 to 4.9% in Jun-25.

Consumer Healthcare

• Revenue up 15% YoY, with e-commerce and modern trade share rising to 11% (from 9%).
• New launches gaining traction: Epic ThinX (premium condoms), Nimulid (pain), and OvaNews (ovulation kit).

Exports

• Revenue surged 81.1% YoY, primarily due to BSV consolidation and continued growth in the base business.
• In the US, one new product was launched in Q1FY26, taking the cumulative total to 45 products.

Management Commentary

“Mankind’s revenue grew by 24.5% with EBITDA margins at 23.8% in Q1FY26 led by continued 1.4x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation,” said Mr. Rajeev Juneja, Vice Chairman and MD. He further said, “We remain confident of delivering healthy performance this year onwards. As we celebrate 30 years of operations, we’ve approved an interim dividend of ₹1 per share for our shareholders.”

About Mankind Pharma

Mankind Pharma Ltd, headquartered in New Delhi, is one of India’s largest pharmaceutical companies with a strong domestic focus across acute and chronic therapies. It operates leading brands in OTC categories like Manforce, Gas-O-Fast, and Preganews, and has a wide manufacturing footprint with 30 facilities and 7 R&D centres. The company is listed on both NSE and BSE and has a workforce of over 18,000 medical reps and a distribution reach covering 5 lakh doctors across India.

REF:https://nsearchives.nseindia.com/corporate/MANKIND4_31072025175727_31072025Press_Release_Q1_FY26_sd.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations